Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2025-07-04 Investor Presentation
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(증권예탁증권)
Investor Presentation Classification · 98% confidence The document is a '증권신고서(증권예탁증권) 정정신고' (Amendment to Securities Registration Statement) filed by NeoImmuneTech. In the context of Korean financial regulations (DART system), a Securities Registration Statement (증권신고서) is a formal regulatory filing required when a company intends to offer securities to the public. The document contains detailed information about the company's drug development pipeline (NIT-110, NIT-112, NIT-119), clinical trial progress, and risk factors, which are standard components of a registration statement. Since it does not fit into specific categories like 10-K or Earnings Release, and is a formal regulatory filing, it is classified as a Regulatory Filing (RNS).
2025-07-04 Korean
[기재정정]증권신고서(증권예탁증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서(증권예탁증권) 정정신고' (Amendment to Securities Registration Statement) filed by NeoImmuneTech. It details specific corrections made to the original filing (submitted on May 30, 2025) in response to a request from the Financial Supervisory Service (FSS). The content includes updates to risk factors, financial information, and technical descriptions of their drug pipeline (NT-I7). Since this is a formal regulatory filing for a securities registration amendment, it falls under the 'Regulatory Filings' category.
2025-06-20 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from NeoImmuneTech regarding a decision to issue new shares (유상증자결정). It details the capital increase method, share allocation, pricing, and subscription dates. This falls under the category of announcements regarding new share issues or capital changes.
2025-05-30 Korean
증권신고서(증권예탁증권)
Capital/Financing Update Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a capital increase (rights offering) for NeoImmuneTech, Inc., including risk factors, financial status, and offering details. This is a formal regulatory filing required for public offerings of securities, which falls under the category of Regulatory Filings (RNS) as it is a primary regulatory document for capital raising.
2025-05-30 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling and purpose of an 'Investor Relations (IR) Meeting' (기업설명회). It provides details such as the date, time, location, target audience, and the specific clinical trial data (NIT-112) to be discussed. Since this is an announcement of an upcoming event rather than the presentation slides themselves or a comprehensive financial report, it falls under the category of a regulatory announcement regarding corporate activities.
2025-05-20 Korean
투자판단관련주요경영사항(임상시험결과) (NIT112 (거대 B세포 림프종, NTI7 및 CART 치료제 병용 요법) 임상 1b상 Topline Data 발표)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean biotech company (NeoImmuneTech) regarding the results of a Phase 1b clinical trial. It details the clinical trial name, methodology, safety data, and efficacy results (Topline Data). In the context of financial filings, particularly for publicly traded companies, announcements of clinical trial results are classified as 'Regulatory Filings' (RNS) because they are mandatory disclosures of material information that do not fit into specific categories like 'Earnings Release' or 'Annual Report'.
2025-05-19 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.